Perioperative pembrolizumab enhances survival rates in advanced head and neck cancer, paving the way for earlier ...

Combination cohort initiated following successful review of monotherapy cohortOver 100 participants dosed to-date in ...

FDA approvals and long-term study results, showcasing advancements in cancer treatments, and patient care strategies.

Keytruda (pembrolizumab) is approved for head and neck squamous cell carcinoma as a perioperative treatment regimen.

Pembrolizumab, an immune checkpoint inhibitor, has been approved by the U.S. Food and Drug Administration (FDA) for the ...

The American Journal of Managed Care provides insights into the latest news and research in managed care across multimedia ...

In this video, Susana M. Campos, MD, MPH, discusses results from the final analysis of the phase 3 A18 study in advanced cervical cancer, presented at ASCO Annual Meeting.The ...

In this video, Susana M. Campos, MD, MPH, discusses results from a single-arm phase 2 study of the concurrent treatment of vulvar cancer with chemoradiation and pembrolizumab.Patients who underwent ...

The FDA approved pembrolizumab (Keytruda) for patients with PD-L1-positive resectable locally advanced head and neck squamous ...

Alvotech and Dr. Reddy’s have entered into a collaboration and license agreement to co-develop, manufacture and commercialize ...

Keytruda (pembrolizumab) is now approved as perioperative treatment for patients with head and neck squamous cell carcinoma.

Dr. Jared Weiss walks patients through the therapeutic potential viability of intratumoral therapies among those with lung ...